What Are Conjugate Vaccines and How Do They Work?

Conjugate vaccines work by chemically linking a sugar molecule from a bacterium’s outer shell to a carrier protein, tricking the immune system into mounting a far stronger and longer-lasting response than the sugar alone could trigger. This technique solved one of the most stubborn problems in vaccinology: many of the deadliest bacteria hide behind a sugar-based capsule that young children’s immune systems simply cannot recognize well enough to fight. By attaching those sugars to a protein, vaccine developers transformed weak, forgettable immune targets into ones that activate the full power of immune memory, and the results have been dramatic.

Why Bacteria Wear Sugar Coats

Many dangerous bacteria, including those that cause meningitis, pneumonia, and bloodstream infections, surround themselves with a thick capsule made of polysaccharides (complex sugar chains). This capsule is not just structural. It actively shields the bacterium from your immune defenses. The capsule blocks complement proteins from tagging the bacterium for destruction, hides the surface markers that antibodies would normally latch onto, and interferes with the ability of immune cells called neutrophils to engulf and kill the invader.¹ Research on the pneumococcus, one of the most medically important encapsulated bacteria, has confirmed that removing the capsule makes the bacterium dramatically more vulnerable to every branch of immune attack, from antibody-driven killing to direct engulfment by white blood cells.²

The capsule’s sugars are also the most obvious target for a vaccine. If you could train the immune system to recognize and attack those polysaccharides, you could strip away the bacterium’s main defense. Early polysaccharide vaccines tried exactly that, injecting purified capsular sugars to stimulate antibody production. They worked reasonably well in older children and adults, but they had a critical blind spot.

The Problem With Plain Polysaccharide Vaccines

Polysaccharides, on their own, stimulate the immune system through a pathway that does not involve T cells, one of the key players in building lasting immunity. Without T-cell help, the body produces a short-lived antibody response, generates little to no immune memory, and cannot mount a stronger response upon re-exposure. This matters most in children under two years old, whose immune systems are especially poor at responding to polysaccharides alone. Research has shown that the region of the spleen responsible for rapid secondary immune responses (the marginal zone) is populated by inexperienced, naive immune cells in infants and does not mature fully until around age two to five.³ That left the youngest and most vulnerable patients largely unprotected by the older generation of polysaccharide vaccines.

Repeated doses of plain polysaccharide vaccines can actually make things worse. Studies have found that giving additional doses of polysaccharide vaccine can induce a state of hyporesponsiveness, where the immune system responds less strongly to each subsequent dose rather than more strongly.⁴ In one trial, children who received a 23-valent polysaccharide vaccine at 12 months showed a profound lack of response when challenged again with the same polysaccharide, while children who had not received the earlier dose responded normally.⁵ Similar hyporesponsiveness has been documented with repeated meningococcal polysaccharide vaccination.⁶ Conjugate vaccines were designed specifically to overcome both of these limitations.

How Conjugation Changes the Immune Response

The core idea is straightforward: take the polysaccharide you want the immune system to target and covalently attach it to a protein that the immune system already knows how to handle. The protein serves as a carrier, dragging the sugar into a different, much more effective arm of immunity. Instead of bypassing T cells, the conjugate enters the pathway where T cells actively help B cells produce high-quality, long-lasting antibodies.⁷

Here is roughly what happens after you receive a conjugate vaccine. Immune cells called B cells recognize and take up the sugar-protein complex. They break down the carrier protein into fragments and display those fragments on their surface. T cells recognize those protein fragments and, in response, provide chemical signals that help the B cells mature, switch to producing more effective antibody types, and form memory cells. The result is a stronger initial antibody response, a population of long-lived memory cells that can respond rapidly to future encounters, and the ability to mount a booster response if exposed again.⁸

Mouse studies have confirmed that this process depends on specific molecular interactions between T cells and B cells. When researchers knocked out any of the key signaling molecules involved in T-cell-B-cell cooperation, the switch to high-quality antibodies was abolished entirely.⁹ The memory response is also more nuanced than a simple expansion of all antibody types. Research tracking the immune response over weeks found that memory B cells in the blood expanded within about two weeks of vaccination, while deeper immune structures called germinal centers peaked later, around four weeks, and their response was dominated by a narrow set of antibody specificities rather than a broad mix.¹⁰

The Carrier Proteins

Only a handful of carrier proteins are used in licensed conjugate vaccines. The three most common are tetanus toxoid, diphtheria toxoid, and CRM197, a nontoxic mutant form of diphtheria toxin.¹¹ All three are proteins the immune system is already familiar with, since most people have received diphtheria and tetanus vaccinations in childhood. That prior exposure is actually helpful: it means the T cells needed to assist the immune response to the conjugate are already primed and ready. As a bonus, these carrier proteins also boost antibody responses against themselves, providing additional protection against diphtheria or tetanus.¹²

Other carrier proteins have been explored, including outer membrane protein complexes from bacteria. One Hib conjugate vaccine uses an outer membrane protein complex from meningococcus as its carrier, and this particular formulation has shown strong immunogenicity in infants.¹³ Newer conjugate candidates for diseases like shigellosis have used a recombinant fragment of the tetanus toxin heavy chain as a carrier, which is easier to produce at scale than full tetanus toxoid.¹⁴

How the Sugar Gets Attached to the Protein

The chemistry of conjugation matters more than you might expect, because the way the sugar is linked to the protein affects how the immune system processes the whole complex. Licensed vaccines typically use polysaccharides that are chemically modified and then randomly linked at multiple points along their chain to the carrier protein.¹⁵ The polysaccharide chains can also be shortened (“sized”) before attachment, which gives a more defined structure and can improve consistency between vaccine batches.

A newer approach bypasses the traditional chemistry entirely. Known as bioconjugation or Protein Glycan Coupling Technology, this method engineers bacteria (usually E. coli) to assemble the sugar-protein conjugate inside living cells. The bacterium’s own machinery attaches the polysaccharide to the carrier protein, eliminating the need for chemical coupling steps.¹⁶ Researchers have demonstrated both a well-characterized N-linked system and an O-linked glycosylation system that can transfer a wide range of sugar structures to protein carriers, even working directly inside pathogenic bacteria like Shigella.¹⁷ The promise of bioconjugation is lower manufacturing cost and greater flexibility, which could be especially important for making conjugate vaccines affordable in lower-income countries.

Quality Control Challenges

One persistent headache in conjugate vaccine manufacturing is controlling the amount of “free” (unconjugated) polysaccharide in the final product. Free polysaccharide has not been linked to a carrier protein, so it stimulates the weaker, T-cell-independent pathway and can potentially induce the hyporesponsiveness described earlier. Manufacturers need sensitive methods to measure it. Techniques include precipitating the conjugated material and measuring the leftover sugar, or using chromatographic methods that separate free polysaccharide from the conjugate based on size.¹⁸ Some validated methods can detect free polysaccharide at levels below one percent of the total.¹⁹ For Hib vaccines specifically, where the polysaccharide contains a distinctive sugar-alcohol backbone, dedicated chromatographic and colorimetric assays have been developed to quantify both total and free polysaccharide content.²⁰

The Hib Success Story

The clearest demonstration of what conjugate vaccines can accomplish came with Haemophilus influenzae type b (Hib). Before vaccination, Hib was the leading cause of bacterial meningitis in young children in many countries. Early work showed that coupling the Hib capsular polysaccharide to carrier proteins dramatically increased immunogenicity in infants, who had been unprotected by earlier polysaccharide-only vaccines.²¹ After conjugate vaccines were introduced into the US infant schedule in 1991, invasive Hib disease dropped by about 99%, falling to fewer than 0.3 cases per 100,000 people in all age groups.

Technology transfer efforts have since brought Hib conjugate vaccine production to manufacturers in India, Indonesia, Korea, and China, helping ensure a sustainable supply of affordable doses for lower-income countries.²² The Hib experience became the template for every conjugate vaccine that followed.

Herd Protection and Carriage Reduction

One of the unexpected bonuses of conjugate vaccines is that they do not just protect the vaccinated person. They also reduce the bacterium’s ability to colonize the throat, which means vaccinated individuals are less likely to carry and transmit the organism to others. This creates herd protection, shielding unvaccinated people as well. Meningococcal serogroup C conjugate vaccines reduced throat carriage of the targeted strain by about 75%, and this reduction persisted for at least two years after vaccination.²³ When conjugate vaccines are used in the age groups that carry the bacterium most frequently, the indirect protection to unvaccinated people can be substantial.²⁴

Modeling of pneumococcal conjugate vaccine data in the United States showed significant declines in disease caused by vaccine-targeted strains among unvaccinated adults aged five and older. The indirect effect grew as children received more doses: with three or more doses on average in the vaccinated childhood population, disease from vaccine strains in unvaccinated adults dropped by about three-quarters.²⁵ Plain polysaccharide vaccines, by contrast, do not meaningfully affect carriage and therefore do not generate this kind of community-wide protection.

The Serotype Replacement Problem

Conjugate vaccines target specific strains defined by their capsular sugar type (serotype). When you suppress the targeted strains, you open ecological space for non-vaccine strains to fill. This serotype replacement is a real and well-documented phenomenon with pneumococcal conjugate vaccines. After the 7-valent vaccine (PCV7) was introduced, disease caused by vaccine serotypes fell sharply, but disease from non-vaccine serotypes gradually rose, partially offsetting the gains.²⁶

The replacement process follows a fairly predictable pattern. After a new conjugate vaccine is introduced, non-vaccine serotypes rise in abundance for a period, then the community eventually settles into a new equilibrium with a different mix of serotypes. Modeling of surveillance data estimated the half-life of the replacement process at roughly eight years for PCV7 and ten years for PCV13.²⁷ The replacement serotypes also vary between countries and age groups, which complicates the strategy of simply adding more serotypes to the vaccine. Newer formulations with 15 or 20 serotypes are in use or in development, but the fundamental challenge remains: each new vaccine will suppress its targeted strains and potentially create space for others.

The Meningococcal Group B Challenge

Not every capsular polysaccharide lends itself to the conjugate approach. The serogroup B meningococcus has a capsule made of polysialic acid, a sugar chain that is chemically identical to molecules found on the surface of human brain cells during development. A straightforward conjugate vaccine against this capsule could, in theory, trigger antibodies that attack the body’s own tissues or fail to elicit a response because the immune system has learned to tolerate its own polysialic acid.²⁸

Researchers have spent decades trying to work around this. One approach chemically modifies the serogroup B polysaccharide by swapping one chemical group for another (N-propionylation), creating a molecule that mimics a protective target on the meningococcal surface without closely resembling human tissue. Antibodies raised against this modified conjugate were highly bactericidal and showed very low or no recognition of the human version of polysialic acid.²⁹ Another strategy used protein-based mimics of the protective epitope, sidestepping the polysaccharide altogether while still generating antibodies that could kill group B meningococci without attacking human cells.³⁰ The licensed meningococcal B vaccines now in use take a different route entirely, using bacterial surface proteins rather than polysaccharide, but the serogroup B story illustrates the limits of the conjugate approach when the target sugar is too similar to something human.

Conjugate Vaccines in Older Adults

Although conjugate vaccines were developed primarily to protect infants, they also offer advantages for older adults, whose immune systems gradually weaken with age. A study comparing the 7-valent pneumococcal conjugate vaccine with the 23-valent plain polysaccharide vaccine in people with chronic obstructive pulmonary disease found that the conjugate vaccine produced a superior immune response at one month after vaccination. Older age and prior polysaccharide vaccination both reduced how well people responded, underscoring the value of using the conjugate formulation from the start rather than after repeated polysaccharide doses.³¹

Typhoid conjugate vaccines have also been tested across a wide age range. A study of Typbar TCV, a typhoid conjugate vaccine, found that it was safe and produced similar antibody levels in adults aged 18 to 65 and in adults over 65, suggesting that the conjugate approach holds up even in elderly populations.³² This is good news for the expanding use of conjugate vaccines in adult immunization schedules, where the limitations of plain polysaccharide vaccines have long been recognized.

Cost and Access Barriers

Conjugate vaccines are more complex and expensive to manufacture than plain polysaccharide vaccines. Pneumococcal conjugate vaccines are among the priciest routine childhood vaccines. In the US private market, a single dose can cost more than $200, though cooperative procurement mechanisms bring the price down considerably. Through the Pan American Health Organization’s joint purchasing system, pneumococcal conjugate vaccine runs roughly $2 to $12 per dose, and middle-income countries purchasing through UNICEF pay approximately $14 to $45 per dose.³³ Even at negotiated prices, cost remains a major barrier for the countries that have yet to introduce pneumococcal vaccination, many of which bear the heaviest burden of pneumococcal disease. Bioconjugation technology, which could simplify manufacturing, is one potential pathway to lowering costs further over time.

Future Targets for Conjugate Vaccines

The conjugate approach is being extended to pathogens that have resisted vaccine development for decades. Shigella, a leading cause of severe diarrheal disease in young children in low-income countries, is a prime target. Candidate vaccines linking Shigella surface polysaccharides to carrier proteins have shown promising results in animal models, inducing serotype-specific antibody responses and protecting against live bacterial challenge in both mice and guinea pigs.³⁴ These vaccines use platform-style conjugation chemistry that could be adapted for different Shigella serotypes, potentially streamlining development across the diverse Shigella species circulating in endemic regions.

Beyond infectious disease, the conjugation principle has even been explored for nontraditional targets. Nicotine conjugate vaccines, for instance, attach nicotine molecules to carrier proteins to try to generate antibodies that bind nicotine in the bloodstream before it reaches the brain. Early mouse studies with these vaccines, using modern adjuvant combinations rather than traditional aluminum salts, have produced high anti-nicotine antibody levels.³⁵ Whether this translates into an effective tool for smoking cessation in humans remains to be seen, but it demonstrates how broadly the conjugation concept can be applied whenever you need the immune system to notice a molecule it would otherwise ignore.